SMARCA4 and neoplasm: While SMARCA4 mutations seems to be highly specific of SCCOHT, molecular screening for this mutation may not be feasible in routine practice.9 Previous studies have evaluated the sensitivity and specificity of SMARCA4 loss by IHC to differentiate SCCOHT from the more frequent epithelial ovarian cancers, mainly high grade serous histology,11,16 but these tumours are unlikely to be confused histologically with SCCOHT.